Eli Lilly (LLY): Customer relationships that drive and discipline growth

Eli Lilly operates as an integrated pharmaceutical company that discovers, develops, manufactures, markets and sells human pharmaceutical products worldwide, and it primarily monetizes through product sales to wholesalers, pharmacy benefit managers, insurers and health systems, supplemented by selective divestitures of product rights and asset sales. This combination of high-margin, brand-led product sales and periodic monetization of non-core assets creates a revenue profile that is concentrated around a small number of blockbuster products while remaining globally distributed. If you track counterparties, supply footprint and divestiture activity, you see how Lilly manages cash flow, capital allocation and manufacturing scale. For a closer look at customer-linked signals, visit https://nullexposure.com/.

How Lilly’s customer posture shapes the business

Eli Lilly’s operating model is a seller-distributor-manufacturer hybrid: the company develops and manufactures products in-house and sells them through an established commercial network. According to Eli Lilly’s 2025 Form 10‑K, the company recognizes revenue when customers obtain control of shipped goods, and its commercial teams “market, distribute, and sell the products” globally. That commercial posture combined with manufacturing capability creates direct exposure to downstream payors and intermediaries.

Important company-level signals from public filings and disclosures:

• Global reach: Lilly sells products in roughly 90 countries and reports operations across North America, EMEA and APAC, which gives it diversified geographic demand but also multi-jurisdictional payer complexity (FY2025 10‑K).
• Payer mix and government exposure: The company’s customer base explicitly includes governments, managed care organizations and long‑term care institutions, and Lilly records rebates and accruals tied to Medicaid, Medicare and managed care programs—so public payors are a meaningful counterparty class (FY2025 10‑K).
• Concentration at the distribution layer: In 2023–2025, three U.S. wholesale distributors—McKesson, Cencora and Cardinal Health—each accounted for a significant percentage of consolidated revenue, signaling operational dependence on a small set of large intermediaries (FY2025 10‑K).
• Product criticality: Cardiometabolic franchises are now dominant: Mounjaro and Zepbound together generated 56% of total revenues in 2025, making the company’s revenue profile highly sensitive to that therapeutic cluster (FY2025 10‑K).
• Single-segment maturity: Lilly reports as a single business segment—human pharmaceuticals—reflecting a mature, focused portfolio where scaling incumbents matter more than early-stage diversification.

These are not isolated statistics; they define the company’s contracting posture: Lilly negotiates with large payors and distributors, manages rebate accruals, and balances vertical integration in manufacturing with selective divestitures to optimize capital and focus.

Three recent customer and counterparty moves to know now

Below are the concrete relationships and transactions disclosed in public materials. Each is summarized in plain English with source context.

Amphastar Pharmaceuticals — Baqsimi rights transfer

In 2023 Lilly sold the commercial rights for Baqsimi, a cardiometabolic health product, to Amphastar Pharmaceuticals, signaling the company’s active portfolio pruning and monetization of non-core or legacy products as it concentrates resources on its high-growth cardiometabolic franchise. This disposition is noted in Lilly’s FY2025 Form 10‑K.

Source: Eli Lilly 2025 Form 10‑K (discussion of 2023 rights sale of Baqsimi to Amphastar).

Cheplapharm Arzneimittel GmbH — Olanzapine / Zyprexa portfolio

Also in 2023 Lilly sold the olanzapine portfolio, including the branded Zyprexa product, to Germany-based Cheplapharm, which reflects a broader strategy of divesting mature neuroscience assets while reallocating capital toward faster-growing therapeutic areas. Lilly described this transaction in its FY2025 Form 10‑K.

Source: Eli Lilly 2025 Form 10‑K (disclosure of 2023 sale of the olanzapine portfolio to Cheplapharm).

Celltrion Inc. — Branchburg, NJ plant sale

South Korea’s Celltrion agreed to acquire Lilly’s Branchburg, New Jersey manufacturing site for about 460 billion won (roughly $330 million), establishing Celltrion’s first U.S. manufacturing base and indicating Lilly’s willingness to monetize physical manufacturing capacity when it aligns with its strategic footprint. The transaction was reported by KED Global in March 2026.

Source: KED Global / Korea Economic Daily report, March 2026 (news of Celltrion’s acquisition of the Branchburg, NJ plant from Eli Lilly).

If you want to track how these kinds of counterparty moves alter counterparty risk and revenue composition over time, see https://nullexposure.com/ for ongoing monitoring.

What these relationships imply for investors and operators

There are four practical takeaways from this cluster of relationships and the company-level constraints cited in Lilly’s filings:

• Strategic focus through divestiture: Selling Baqsimi and the olanzapine portfolio demonstrates an active effort to redeploy proceeds away from legacy products toward core high-growth franchises. That reduces exposure to slower-growth categories while crystallizing cash.
• Manufacturing footprint optimization: The Branchburg plant sale to Celltrion suggests Lilly will continue to rationalize physical assets where third-party capacity or in-house consolidation is more capital-efficient.
• Concentration and counterparty risk: Dependence on a few large U.S. wholesalers and heavy revenue weighting into cardiometabolic drugs create high-impact counterparty and product concentration risk, which investors must stress-test in scenario analysis.
• Payer complexity as an operational lever and risk: Significant government and managed‑care exposure means Lilly’s receivables, rebate accruals and net pricing are tightly coupled to public policy and payer negotiations—an operational reality embedded in its contracting posture.

These conclusions derive from company disclosures in the 2025 Form 10‑K and contemporaneous press reporting on the plant sale; they should guide underwriting of credit exposure, vendor negotiations and M&A playbooks for competitors and partners.

Near-term indicators to watch

• Monitor disclosures of rebate and accrual levels in quarterly filings to gauge how payer negotiations and government exposure are evolving.
• Watch production and capacity commentary after the Branchburg sale to see whether Lilly increases outsourcing or consolidates remaining sites.
• Track any further rights sales or licensing moves—continued divestitures are a clear signal of capital allocation toward the cardiometabolic franchise.

For deeper tracking and historical context on counterparties, visit https://nullexposure.com/—their coverage helps investors convert these relationship signals into actionable risk assessments.

Bottom line: focused portfolio, concentrated levers

Eli Lilly’s recent customer and counterparty activity shows a deliberate shift toward concentrating capital and commercial effort on its cardiometabolic leaders, while monetizing non-core products and select manufacturing assets. That strategy sharpens upside if the core franchises hold, but increases exposure to distributor concentration, payer negotiations and product-specific demand shocks. Investors should weigh the trade-off between concentrated growth and concentrated counterparty risk when modeling Lilly’s forward cash flows. If you want continuous visibility into how these relationships evolve and what they mean for credit and commercial risk, start here: https://nullexposure.com/.